Evaluation of anakinra in the management of patients with COVID-19 infection: A randomized clinical trial.

ABSTRACT:

Background

The global COVID-19 pandemic led to substantial clinical and economic outcomes with catastrophic consequences. While the majority of cases has mild to moderate disease, minority of patients progress into severe disease secondary to the stimulation of the immune response. The hyperinflammatory state contributes towards progression into multi-organ failure which necessitates suppressive therapy with variable outcomes. This study aims to explore the safety and efficacy of anakinra in COVID-19 patients with severe disease leading to cytokine release syndromes.

Methods

In this open-label, multi-center, randomized clinical trial, patients with confirmed COVID-19 infection with evidence of respiratory distress and signs of cytokine release syndrome were randomized in 1:1

SUBMITTER: Elmekaty EZI 

PROVIDER: S-EPMC9910697 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature